Company Encyclopedia
View More
name
TONGRENTANGCM
03613.HK
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals. It operates through three segments: Hong Kong, Mainland China, and Overseas. The company offers Chinese medical consultation and treatment services. It also operates retail outlets in Hong Kong and in other countries and regions in Asia, Oceania, North America, and Europe.
1.450 T
03613.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking10/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE13.16%B
    • Profit Margin30.16%A
    • Gross Margin60.79%A
  • Growth ScoreB
    • Revenue YoY24.13%A
    • Net Profit YoY4.30%C
    • Total Assets YoY6.00%B
    • Net Assets YoY6.36%B
  • Cash ScoreB
    • Cash Flow Margin331.58%C
    • OCF YoY24.13%A
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreA
    • Gearing Ratio6.89%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tong Ren Tang released its performance for the first three quarters, with a net profit attributable to the parent company of 1.178 billion yuan, a decrease of 12.78%

    According to the Zhitong Finance APP, TONGREN TANG released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 13.308 billion yuan, a year-on-year decrease of 3.70%. The net profit attributable to shareholders of the listed company was 1.178 billion yuan, a year-on-year decrease of 12.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.163 billion yuan, a year-on-year decrease of 11.95%. The basic earnings per share were 0.859 yuan

    Zhitong·
    HK
    03613
    +1.12%
    SH
    600085
    +0.51%
    HK
    01666
    +0.21%
    Zhitong·
    HK
    03613
    +1.12%
    SH
    600085
    +0.51%
    HK
    01666
    +0.21%

    Morning Trend | TONGRENTANGCM's capital shifts, are short-term opportunities coming under regulatory turbulence?

    Tongrentang Guoyao (3613.HK) has recently experienced fluctuations in the market, with funds frequently moving in and out, and changes in the regulatory environment becoming the biggest uncertainty. There is frequent rotation within the sector, and the pharmaceutical track has temporarily been neglected, but it could experience significant volatility due to regulatory policies at any time. The market generally prefers a "tight but not loose" approach, with cautious funds dominating. In the short term, the stock price has tested the lower adjustment boundary multiple times, with widening price spreads, and low-buy high-sell operations dominating the intraday market. Technically, the K-line has repeatedly surged and retreated, with the main force yet to form an effective breakthrough, but the adjustment space is gradually converging. Current market discussions focus on whether the regulatory "boots" will drop, and the sector's shape awaits a catalyst for promotion. Community traders are paying attention to the progress of risk release in the sector, believing that once regulations are implemented, there will be a favorable expectation gap, and pharmaceutical stocks may welcome a collective recovery. Conversely, if policies continue to suppress, more time will be needed for digestion. In terms of fund movement, the main force is more watchful than active, with short-term speculative funds making small bets, and the sector's direction significantly affecting individual stock elasticity. Technically, if the lower support holds and is quickly replenished with volume, it is expected to continue the recovery trend. It is recommended to closely monitor intraday fluctuations and policy news, and to moderately test small positions during the day. If accompanied by significant volume changes from the main force, further positions can be added. If the regulatory environment remains negative, risk control should be prioritized. Currently, it is at a critical juncture, and short-term funds should patiently capture high elasticity

    Technical Forecast·
    HK
    03613
    +1.12%
    Technical Forecast·
    HK
    03613
    +1.12%

    The market value of the hundred billion is in jeopardy! After a 20% plunge in profits, how will "Chinese medicine Moutai" ZZPZH turn the tide?

    ZZPZH faces a turning point in the traditional Chinese medicine industry in 2025, with the third quarterly report showing a sharp decline in both revenue and net profit, down 11.9% and 20.7% respectively. The market value has dropped from 270 billion yuan in 2021 to 109.031 billion yuan, evaporating nearly 60%. A structural turning point is emerging in the overall industry, with traditional growth models gradually disappearing. ZZPZH needs to explore new growth methods to meet the challenges

    Wallstreetcn·
    SZ
    000538
    +0.36%
    HK
    03613
    +1.12%
    SH
    600436
    +0.12%
    Wallstreetcn·
    SZ
    000538
    +0.36%
    HK
    03613
    +1.12%
    SH
    600436
    +0.12%

    TONGRENTANGCM has been issued a "Traditional Medicine Registration License"

    TONGRENTANGCM recently obtained the "Traditional Medicine Registration License" issued by the Cambodian Ministry of Health, allowing its "TONGRENTANGCM An Gong Niu Huang Wan" to be sold in Cambodia. This medicine must be used under the guidance of a licensed traditional Chinese medicine practitioner. The acquisition of this license will enrich the company's distribution channels and assist in market expansion, but the impact on the company's performance is limited, as sales are still affected by factors such as policies, exchange rates, and market competition

    Zhitong·
    HK
    03613
    +1.12%
    Zhitong·
    HK
    03613
    +1.12%

    TONGRENTANGCM: Yan Han appointed as Chairman of the Board

    According to the announcement from TONGRENTANGCM, Gu Haiou will retire as the company's executive director, chairman of the board, and authorized representative under Rule 3.05 of the Hong Kong Stock Exchange's listing rules due to reaching retirement age, effective September 4, 2025. The company's executive director Yan Han has been appointed as the chairman of the board, effective September 4, 2025. The company's executive director and vice chairman of the board Le Zheng has been appointed as the authorized representative, effective September 4, 2025

    Zhitong·
    HK
    03613
    +1.12%
    Zhitong·
    HK
    03613
    +1.12%
    © 2025 Longbridge｜Disclaimer